Vera Therapeutics, Inc. is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy and lupus nephritis. The company is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections.

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases that improve patients’ lives.

Vera Therapeutics, Inc.

We’re #hiring! #Joinourteam and take part in our mission to improve the standard of care for patients with serious immunological diseases.
Learn about our open positions here: https://lnkd.in/d2-8KHTC 

Today we announced our Q3 business update and financial results. Read the full release here: https://lnkd.in/df4BxFuY

Dr. Richard Lafayette, MD, FACP, spoke with HCPLive about the additional week 36 analyses from our ORIGIN Phase 2b clinical trial in #IgAN presented at ASN Kidney Week 2023. Watch the interview here: https://lnkd.in/d8eauakC
#kidneywk #IgANephropathy

Today we're presenting two posters with new week 36 analyses from our Phase 2b ORIGIN trial in #IgANephropathy at American Society of Nephrology Kidney Week: https://lnkd.in/dZtKAfQX
Be sure to stop by our posters SA-PO884 and SA-PO887 and visit us at booth 2321! 
#Kidneywk

We’re live at American Society of Nephrology Kidney Week 2023! Come to booth #2321 to learn about our research in #IgANephropathy. And don’t miss our poster presentations on Saturday: https://lnkd.in/dZpvugVK
#kidneywk

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

COM:VERATX

Vera Therapeutics, Inc.

Last Close

49.04

08/11 21:00

Market Cap

2.00B

Beta: -

Volume Today

599.65K

Avg: -

Analysis Not Available